12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Shire, Swedish Orphan Biovitrum sales and marketing update

Swedish Orphan said Shire plans to regain marketing and distribution rights to Xagrid anagrelide to treat thrombocytopenia, Fosrenol lanthanum carbonate to...

Read the full 102 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >